Clinical trials: Advanced Solid Malignancy
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor
Study to Assess AFM24 in Advanced Solid Cancers
AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has…
- Trial name
- NCT04259450
- Testing
- 14 mg AFM24, 40 mg AFM24, 80 mg AFM24
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 85 people
- Sponsor
- Affimed GmbH
Unresectable Locally Advanced or Metastatic Cancer
First-in-Human Study of TAK-280 in Participants With Solid Tumors
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to…
- Trial name
- NCT05220098
- Testing
- TAK-280
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 69 people
- Sponsor
- Takeda
Advanced Solid Tumors
Study of ABT-700 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
- Trial name
- NCT01472016
- Testing
- ABT-700, docetaxel, FOLFIRI
- Volunteers
- 74 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced or Metastatic Solid Tumors
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Combination with AK104 in…
- Trial name
- NCT04572152
- Testing
- AK119, AK104
- Where
- 5 sites in Australia
- Volunteers
- 23 people
- Sponsor
- Akeso
Neoplasms, Lung
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers.
- Trial name
- NCT07602855
- Testing
- Risvutatug rezetecan, Ivonescimab
- Where
- 4 sites in United States, Japan
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
This is a phase 1b/2, open-label, two-part, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod injections alone and in…
- Conditions
- Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03684785
- Testing
- Cavrotolimod, Pembrolizumab, Cemiplimab
- Where
- 26 sites in United States
- Volunteers
- 57 people
- Sponsor
- Exicure, Inc.
Tumors, Neoplasms
Phase I Study of LB-100 With Docetaxel in Solid Tumors
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel.
- Conditions
- Tumors, Neoplasms, Cancer
- Trial name
- NCT01837667
- Testing
- LB-100 for Injection, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lixte Biotechnology Holdings, Inc.
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Digestive Cancer, Breast Cancer
- Trial name
- NCT05961111
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Advanced Solid Tumor, Esophageal Cancer
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with…
- Conditions
- Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers
- Trial name
- NCT06682806
- Testing
- PRT3789, pembrolizumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Prelude Therapeutics Incorporated
Advanced Solid Tumors, Platinum Resistant Ovarian Cancer
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT06792552
- Testing
- SIM0505 for injection
- Where
- 17 sites in United States, China
- Volunteers
- 738 people
- Sponsor
- NextCure, Inc.
Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
- Trial name
- NCT07524348
- Testing
- E303
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 149 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Advanced Solid Tumor
A Study of DS5361b in Participants With Advanced Solid Tumors
This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.
- Trial name
- NCT07182591
- Testing
- DS5361b, Pembrolizumab
- Where
- 7 sites in United States, Japan
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
Solid Cancers
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with…
- Trial name
- NCT00927589
- Testing
- carboplatin, docetaxel, trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 59 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Adult
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
Protocol GVO-1102 is a phase 1, open label, multi-center study in adult patients with locally advanced or metastatic solid tumors. This study includes two parts: dose escalation and dose expansion.
- Trial name
- NCT06391918
- Testing
- GEN2 + Valganciclovir
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- GenVivo, Inc.
Advanced Solid Tumors
SKB103 for Injection in Advanced Solid Tumors
This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
- Trial name
- NCT07459998
- Testing
- SKB103 for injection monotherapy
- Where
- 2 sites in China
- Volunteers
- 277 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Neoplasms
A Study of RO5458640 in Patients With Advanced Solid Tumors
This multicenter, open-label, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO5458640 in patients with advanced solid tumors.
- Trial name
- NCT01383733
- Testing
- RO5458640
- Where
- 4 sites in Canada, Denmark and 1 more
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
- Trial name
- TMB-H (NCT06365840)
- Testing
- IMC-001
- Where
- 4 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Solid Cancers, Solid Tumours
A Study to Evaluate the Safety and Tolerability of EP0089
This is a first-in-human (FIH), first-in-class, Phase I/IIa, open-label study designed to evaluate the safety and tolerability of EP0089 (study drug).
- Trial name
- NCT07030478
- Testing
- EP0089-101
- Volunteers
- 190 people
- Sponsor
- Ellipses Pharma
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca